- Home
- YORW vs URGN Comparison
YORW vs URGN Comparison
Compare YORW & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YORW
- URGN
- Stock Information
- Founded
- YORW 1816
- URGN 2004
- Country
- YORW United States
- URGN United States
- Employees
- YORW N/A
- URGN N/A
- Industry
- YORW Water Supply
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- YORW Utilities
- URGN Health Care
- Exchange
- YORW Nasdaq
- URGN Nasdaq
- Market Cap
- YORW 546.3M
- URGN 547.1M
- IPO Year
- YORW N/A
- URGN 2017
- Fundamental
- Price
- YORW $36.18
- URGN $11.91
- Analyst Decision
- YORW
- URGN Strong Buy
- Analyst Count
- YORW 0
- URGN 5
- Target Price
- YORW N/A
- URGN $44.50
- AVG Volume (30 Days)
- YORW 41.0K
- URGN 471.4K
- Earning Date
- YORW 11-07-2024
- URGN 11-06-2024
- Dividend Yield
- YORW 2.33%
- URGN N/A
- EPS Growth
- YORW N/A
- URGN N/A
- EPS
- YORW 1.48
- URGN N/A
- Revenue
- YORW $74,189,000.00
- URGN $89,363,000.00
- Revenue This Year
- YORW $7.70
- URGN $14.43
- Revenue Next Year
- YORW $5.33
- URGN $44.44
- P/E Ratio
- YORW $24.47
- URGN N/A
- Revenue Growth
- YORW 9.03
- URGN 15.64
- 52 Week Low
- YORW $33.32
- URGN $10.60
- 52 Week High
- YORW $41.96
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- YORW 49.20
- URGN 48.14
- Support Level
- YORW $35.30
- URGN $10.62
- Resistance Level
- YORW $36.06
- URGN $12.78
- Average True Range (ATR)
- YORW 0.70
- URGN 0.67
- MACD
- YORW -0.01
- URGN -0.02
- Stochastic Oscillator
- YORW 33.71
- URGN 46.91
About YORW York Water Company (The)
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and two wastewater treatment systems. The company operates within its franchised territory, which covers more than 54 municipalities within York County, Pennsylvania.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.